Understanding and overcoming BTK inhibitor resistance in CLL
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2026-03-10
Просмотров: 16
Описание:
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses mechanisms of resistance to BTK inhibitors in chronic lymphocytic leukemia (CLL), describing how mutations in the BTK binding site and kinase domain can emerge during therapy. She also highlights the evolving landscape of resistance with both covalent and non-covalent BTK inhibitors and outlines potential strategies to overcome it. This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
